For Selank specifically, intranasal delivery is the registered route of administration in the Russian Federation, and the clinical trial data supporting its efficacy were generated using this route. The olfactory and trigeminal pathways provide direct access to the CNS, bypassing the blood-brain barrier for a meaningful fraction of the administered dose. The Pro-Gly-Pro extension in Selank’s sequence was partly designed to resist enzymatic degradation in the nasal mucosa, improving bioavailability relative to the parent tuftsin tetrapeptide. Absolute bioavailability figures are not published, but the clinical response data suggest the route is pharmacologically meaningful.

Tuftsin is a naturally occurring tetrapeptide (Thr-Lys-Pro-Arg) cleaved from the Fc region of IgG by the enzyme tuftsin endocarboxypeptidase. It promotes phagocytic activity, modulates cytokine production, and has mild anxiolytic properties in animal models. Selank was designed at the Institute of Molecular Genetics by appending a Pro-Gly-Pro tripeptide to tuftsin’s C-terminus – a modification that dramatically extends metabolic stability (tuftsin has a plasma half-life of seconds) while preserving and amplifying the parent molecule’s immunomodulatory and CNS-active properties. Selank is, in this sense, a stabilized and pharmacologically enriched version of an endogenous signal.

The literature suggests that Selank’s cognitive effects are most pronounced in subjects with elevated baseline anxiety or under conditions of acute stress – states in which anxiety-driven cognitive interference is the primary limiting factor. In low-anxiety subjects, the cognitive benefit appears attenuated. This pattern is consistent with a stress-buffering mechanism rather than a direct nootropic one: Selank does not appear to enhance cognition above a healthy baseline so much as it protects cognitive function from stress-induced degradation. The distinction matters for setting appropriate expectations.

Published clinical protocols in the Russian literature describe courses of 10–14 days, sometimes extended to 28 days for anxiety disorder treatment. Cycling – typically 10 days on, 10 days off – is recommended in some protocols to preserve receptor sensitivity, though the pharmacological basis for this recommendation is not rigorously established in the published data. No evidence of tolerance development has been reported in trials up to four weeks in duration. Longer-term use patterns are not well characterized in the Western literature.

Regulatory approval in Western jurisdictions requires a specific evidentiary package: large, multicenter, double-blind, placebo-controlled trials conducted under GCP guidelines, with pre-registered endpoints, independent data monitoring, and submission to the relevant authority (FDA, EMA). The Russian clinical data, while genuine and methodologically reasonable within their context, were not generated to meet these standards and have not been submitted through Western regulatory pathways. The compound also lacks a Western commercial sponsor willing to fund the Phase II/III program required for approval. This is a regulatory and commercial gap, not necessarily a scientific one – though the absence of large independent trials remains a legitimate epistemic limitation.